Teppei Hagino

73PUBLICATIONS
7CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)AllergyClinical pharmacology and therapeuticsTraditional Chinese medicine and treatmentsEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (73)

|Oct 12, 2026
Effects of Switching From Deucravacitinib to Tildrakizumab in Psoriasis: A 28-Week Real-World Study.

|Sep 26, 2026
High-Salt Diet Exacerbates Murine Imiquimod-Induced Psoriasis-like Dermatitis via Activation of Serum- and Glucocorticoid-Inducible Kinase 1.

|Aug 13, 2026
Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety.

|Jul 01, 2026
Real-World Effectiveness of Tildrakizumab in Japanese Patients With Psoriasis: Analyses Stratified by Prior Systemic Therapy, Maintenance of Early Responses, and Achievement of Delayed Responses.

|Apr 27, 2026
48-Week Real-World Outcomes of Lebrikizumab Treatment for Atopic Dermatitis: Systemic Therapy-Naive Versus -Experienced Patients.

|Feb 16, 2026
Seventy-Two-Week Real-World Outcomes of Tralokinumab Treatment for Moderate-To-Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity.

Manami Yoneyama, Teppei Hagino, Akihiko Uchiyama

Pageof 13

Frequent Collaborators

46 joint publications

Naoko Kanda

34 joint publications

Hidehisa Saeki

7 joint publications

Eita Fujimoto

4 joint publications

Akihiko Uchiyama